Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-Pure and WJ-Pure in COVID-19 ARDS
NCT05387278Phase 1Suspended
- Sponsor
- Vitti Labs
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles, Tissue Cells
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VL-PX10 and WJ-Pure in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Vitti Labs. Primary endpoints: Safety of EV-Pure and WJ-Pure administration at 3 months and Efficacy of EV-Pure and WJ-Pure at 3 months. Started Mar 2025; status: suspended.
02
Drugs
VL-PX10WJ-Pure
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05387278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387278.